Skip to main content

Advertisement

SpringerLink
Log in

Resected High-Risk Rectal GIST Harboring NTRK1 Fusion: a Case Report and Review of the Literature

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382:973–83. https://doi.org/10.1016/S0140-6736(13)60106-3.

    Article  CAS  PubMed  Google Scholar 

  2. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865–78. https://doi.org/10.1038/nrc3143.

    Article  CAS  PubMed  Google Scholar 

  3. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007;369:1731–41. https://doi.org/10.1016/S0140-6736(07)60780-6.

    Article  CAS  PubMed  Google Scholar 

  4. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006;24:4764–74.

    Article  CAS  Google Scholar 

  5. Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, et al. FGFR1 and NTRK3 actionable alterations in "wild-type" gastrointestinal stromal tumors. J Transl Med. 2016;14:339.

    Article  Google Scholar 

  6. Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol. 2016;2:922–8. https://doi.org/10.1001/jamaoncol.2016.0256.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Brenca M, Rossi S, Polano M, Gasparotto D, Zanatta L, Racanelli D, et al. Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. J Pathol. 2016;238:543–9. https://doi.org/10.1002/path.4677.

    Article  CAS  PubMed  Google Scholar 

  8. Casali PG, Abecassis N, Bauer S et al (2018) Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29 Suppl 4:iv68-iv78. https://doi.org/10.1093/annonc/mdy095.

  9. NCCN Clinical Practice Guidelines in Oncology. Soft tissue sarcoma. Version 6.2019 – February 10, 2020. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf Accessed Apr 8, 2020.

  10. Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21:531–40. https://doi.org/10.1016/S1470-2045(19)30856-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, et al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicenter, open-label phase 2 trial. Lancet Oncol. 2016;17:632–41. https://doi.org/10.1016/S1470-2045(16)00075-9.

    Article  CAS  PubMed  Google Scholar 

  12. Falchook GS, Trent JC, Heinrich MC, et al. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget. 2013;4:310–5. https://doi.org/10.18632/oncotarget.864.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2013;123:340–7. https://doi.org/10.1172/JCI60578.

    Article  CAS  PubMed  Google Scholar 

  14. Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A. 2008;105:8387–92. https://doi.org/10.1073/pnas.0803383105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital Alemão Oswaldo Cruz, São Paulo, Brazil

    Renata D’Alpino Peixoto

  2. Premiere Medicina e Saúde, Fortaleza, Brazil

    Bruno Amaral Medeiros

  3. Centro Regional Integrado de Oncologia (CRIO), Fortaleza, Brazil

    Eduardo Henrique Cronemberger

  4. Pronutrir Oncologia, Fortaleza, Brazil

    Eduardo Henrique Cronemberger

Authors
  1. Renata D’Alpino Peixoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruno Amaral Medeiros
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eduardo Henrique Cronemberger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Renata D’Alpino Peixoto.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

D’Alpino Peixoto, R., Medeiros, B.A. & Cronemberger, E.H. Resected High-Risk Rectal GIST Harboring NTRK1 Fusion: a Case Report and Review of the Literature. J Gastrointest Canc 52, 316–319 (2021). https://doi.org/10.1007/s12029-020-00423-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-020-00423-x

Search

Navigation